Show simple item record

ω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study.

dc.contributor.authorHimmetoglu, Solen
dc.contributor.authorBabalik, Erhan
dc.contributor.authorBozcali, Evin
dc.contributor.authorTOPRAK, SADIK
dc.contributor.authorMihmanli, Ismail
dc.date.accessioned2021-03-03T13:47:07Z
dc.date.available2021-03-03T13:47:07Z
dc.date.issued2013
dc.identifier.citationBozcali E., Babalik E., Himmetoglu S., Mihmanli I., TOPRAK S., "ω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study.", Coronary artery disease, cilt.24, sa.4, ss.328-33, 2013
dc.identifier.issn0954-6928
dc.identifier.otherav_36093f40-7cf3-4276-884c-dde1935d5517
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/40496
dc.identifier.urihttps://doi.org/10.1097/mca.0b013e32835f3005
dc.description.abstractObjective We conducted a clinical trial to examine the effect of omega-3 fatty acids in patients with cardiac syndrome X (CSX). We aimed to evaluate the potential impact of omega-3 fatty acids on endothelial function, oxidative stress, and symptom relief in the CSX.
dc.language.isoeng
dc.subjectKardiyoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectCARDIAC ve CARDIOVASCULAR SİSTEMLER
dc.titleω-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study.
dc.typeMakale
dc.relation.journalCoronary artery disease
dc.contributor.departmentBaltalimani Bone Diseases Training & Research Hospital , ,
dc.identifier.volume24
dc.identifier.issue4
dc.identifier.startpage328
dc.identifier.endpage33
dc.contributor.firstauthorID209506


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record